A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-Month interim analysis

British Journal of Ophthalmology

Volumn 98, Issue SUPPL. 1, 2014, Pages

  Singh, Rishi P ^a   Srivastava, Sunil ^a   Ehlers, Justis P ^a   Bedi, Rumneek ^a   Schachat, Andrew P ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL SUBFIELD THICKNESS; CLINICAL TRIAL; CONTROLLED STUDY; CUBE AVERAGE THICKNESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXUDATIVE MACULAR DEGENERATION; FOLLOW UP; HUMAN; INTRARETINAL FLUID; MACULAR VOLUME; OUTCOME ASSESSMENT; PATIENT HISTORY OF THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANGIOGENESIS; CLINICAL TRIAL; MACULA; NEOVASCULARISATION; RETINA;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-BLIND METHOD; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84900988526     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304798     Document Type: Article

References (25)

1. Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of age-related macular degeneration. Ophthalmology 1999;106:1049-55. (Pubitemid 30191504)
2. Aiello L, Avery RL, Arrigg PG, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-7. (Pubitemid 24356306)
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
4. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65. e55.
5. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
6. Dvorak HF. Vascular permeability Factor/Vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80. (Pubitemid 35266299)
7. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
8. Rakic J, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93. (Pubitemid 36759791)
9. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501.
10. Sivaprasad S, Hykin P. What is new in the management of wet age-related macular degeneration? Br Med Bull 2013:1-11.
11. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
12. CATT Research Group. Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
13. Martin DF, Maguire MG, Fine SL, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group, et al. Ranibizumab and Bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
14. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multi-center cohort study (SEVEN-UP). Ophthalmology 2013:1-8.
15. Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: Long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120:130-9.
16. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of Ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83.
17. Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009;29:723-31.
18. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-205.
19. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012;96:1-2.
20. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
21. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc, 2011. http://www.regeneron.com/Eylea/eylea-fpi.pdf
22. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003;135:194-205. (Pubitemid 36151797)
23. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for Ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.
24. Gasperipi JL, Fawzi AA, Khondkaryan A, et al. bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularization. Br J Ophthalmol 2012;96:14-20.
25. Schachat AP. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol 2013;156:1-2.